

**From:** Prof. Khosrow Adeli – IFCC President

**Date:** October 24<sup>th</sup>, 2023

**Ref:** New IFCC Task Force on Laboratory Medicine Practice Guidelines (TF-LMPG)

**PRESIDENT**

**Prof. Khosrow ADELI**  
Pediatric Laboratory Medicine  
The Hospital for Sick Children  
University of Toronto  
Ontario M5G 1X8 - Canada  
Email: [president@ifcc.org](mailto:president@ifcc.org)

**PRESIDENT-ELECT**

**Prof. Tomris OZBEN**  
Akdeniz University - Medical Faculty  
Department of Clinical Biochemistry  
07070 Antalya - Türkiye  
Email: [ozben@akdeniz.edu.tr](mailto:ozben@akdeniz.edu.tr)

**SECRETARY**

**Dr. David KINNIBURGH**  
Alberta Centre for Toxicology  
University of Calgary  
Alberta T2N 4N1 – Canada  
Email: [dkinnibu@ucalgary.ca](mailto:dkinnibu@ucalgary.ca)

**TREASURER**

**Prof. Alexander HALIASSOS**  
ESEAP - Greek Proficiency Testing Scheme  
for Clinical Laboratories  
GSCC-CB  
GR-106 76 Athens - Greece  
Email: [haliassos@moleculardiagnosics.gr](mailto:haliassos@moleculardiagnosics.gr)

**CORPORATE REPRESENTATIVE**

**Mr. Joseph PASSARELLI**  
Scientific Relations, Roche Diagnostic Operations  
Centralized and Point of Care Solutions  
Research and Development  
Indianapolis, IN 46250-0457 - USA  
Email: [joseph.passarelli@roche.com](mailto:joseph.passarelli@roche.com)

**IFCC REGIONAL FEDERATION  
REPRESENTATIVES**

**African Federation of Clinical Chemistry (AFCC)**  
**Prof. Adekunle Bashiru OKESINA**  
Department of Chemical Pathology and Immunology -  
University of Ilorin  
Kwara State – Nigeria  
Email: [drokesina@yahoo.com](mailto:drokesina@yahoo.com)

**Arab Federation of Clinical Biology (AFCB)**  
**Prof. Abderrazek HEDHILI**  
Laboratoire de Toxicologie CMYAMU  
Montfleury 1008 -Tunisia  
Email: [abderrazek.hedhili@yahoo.fr](mailto:abderrazek.hedhili@yahoo.fr)

**Asia-Pacific Federation for Clinical Biochemistry and  
Laboratory Medicine (APFCB)**  
**Dra. Endang W. HOYARANDA**  
Prodia Clinical Laboratory - Prodia Group  
Jakarta 104030 – Indonesia  
Email: [endang.hoyaranda@prodia.co.id](mailto:endang.hoyaranda@prodia.co.id)

**European Federation of Clinical Chemistry and  
Laboratory Medicine (EFLM)**  
**Prof. Ana-Maria ŠIMUNDIĆ**  
Department of Medical Laboratory Diagnostics  
Clinical Hospital Sveti Duh, Zagreb University  
Zagreb, Croatia  
Email: [am.simundic@gmail.com](mailto:am.simundic@gmail.com)

**Latin-American Confederation of Clinical  
Biochemistry (COLABIOCLI)**  
**Dr. Ana María LENA RODRÍGUEZ**  
Clinical Biochemistry Department  
University of Uruguay  
Montevideo CP 11300 - Uruguay  
Email: [analena@vera.com.uy](mailto:analena@vera.com.uy)

**North American Federation of Clinical Chemistry and  
Laboratory Medicine (NAFCC)**  
**Dr. Edward (Ted) DUNN**  
Clinical Development & Quality Assurance  
Dynacare  
Ontario L6T 5M3 – Canada  
Email: [Dunnt@dynacare.ca](mailto:Dunnt@dynacare.ca)

**IFCC Office**  
Via Carlo Farini, 81  
20159 Milano – Italy  
Tel: +39 02 66809912  
Email: [ifcc@ifcc.org](mailto:ifcc@ifcc.org)  
website: <http://www.ifcc.org/>

**To: IFCC Full Member Societies' National Representatives  
IFCC Affiliate Societies' Representatives  
IFCC Corporate Members' Representatives  
IFCC Regional Federations' Presidents**

Dear All,

The IFCC Executive Board recently launched a very important new program to develop and disseminate best practice recommendations/guidelines in all areas of clinical laboratory medicine and facilitate implementation in clinical laboratories worldwide. After extensive consultation with IFCC Divisions and a steering advisory group, a document detailing the program's Objectives, Scope & Mandate was distributed to IFCC functional groups (see Appendix 1, attached).

IFCC is issuing a call for nominations to create a **new Task Force on Laboratory Medicine Practice Guidelines (TF-LMPG)**, being formed to act as a steering group, provide program oversight, act as a review panel to assess proposals received from functional groups and as last step, forward their recommendations on guidance documents to the IFCC Executive board for final approval.

**Membership:** The Taskforce will consist of a chair and at least 4 full members. Corporate representatives from interested companies can also be members. Term of office: 3 years with the possibility of renewal for a second term pending performance evaluation.

**Meeting Arrangements:** Monthly or bi-monthly virtual meetings as well as 1-2 in person meetings per year, possibly coinciding with an IFCC Congress (EuroMedLab/WorldLab or other events).

**Reporting:** The Taskforce will report to the IFCC Executive Board quarterly with a document summarizing progress made within that quarter.

IFCC National Societies and Corporate Members are invited to nominate experts, sending the documents listed below to Paola Bramati - [paola.bramati@ifcc.org](mailto:paola.bramati@ifcc.org) at the IFCC office **by November 30<sup>th</sup>, 2023:**

- A support letter on behalf of the IFCC Society or Corporate Member, explaining the nominee's interest in the position and the contribution that we can expect from the candidate;
- A short CV.

Taskforce members will be selected from nominations received from national societies and corporate members; however, expertise in areas related to "best practice and preparation of guideline documents" will be considered as an additional criterion for selection of Taskforce members. Nominees that have not been selected can apply to become corresponding members of the Taskforce.

We look forward to receiving nominations from national societies and corporate members around the world.

With kind regards,



Prof. Khosrow Adeli  
IFCC President